Niemann-Pick Disease, A Pipeline Analysis Report 2018

Technavio has published a new report on the drug development pipeline for Niemann-pick disease, including a study of the pipeline molecules.

IPO Launch: Orphazyme A/S Finalizes Terms For $100 Million U.S. IPO - IPOs On TheStreet - U.S. IPO Research & Opinion

Niemann-Pick Disease, A Pipeline Analysis Report 2018, Technavio

Longitudinal MEMRI analysis of brain phenotypes in a mouse model of Niemann- Pick Type C disease - ScienceDirect

Consensus clinical management guidelines for Niemann-Pick disease type C, Orphanet Journal of Rare Diseases

Niemann-Pick-Disease Pipeline, FDA Approvals, Clinical

PDF) Different Niemann-Pick C1 Genotypes Generate Protein Phenotypes that Vary in their Intracellular Processing, Trafficking and Localization

Biomedicines, Free Full-Text

PDF) Different Niemann-Pick C1 Genotypes Generate Protein Phenotypes that Vary in their Intracellular Processing, Trafficking and Localization

Biomarker analysis of Niemann-Pick disease type C using chromatography and mass spectrometry - ScienceDirect

Frontiers Therapeutic Strategies For Tay-Sachs Disease

PDF) Probable Diagnosis of a Patient with Niemann–Pick Disease Type C: Managing Pitfalls of Exome Sequencing

Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease

Niemann-Pick Disease Type C (NPC) Therapeutics - Pipeline Analysis 2019

Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat, Orphanet Journal of Rare Diseases

Frontiers Case Report: Be Aware of “New” Features of Niemann–Pick Disease: Insights From Two Pediatric Cases